Limited benefits of INF-alpha therapy in renal graft candidates with chronic viral hepatitis B or C.
Rodrigues
A
A
Department of Nephrology, Hospital Geral Santo António, Oporto, Portugal.
Morgado
T
T
Areias
J
J
Silvestre
F
F
Pinho
L
L
Alves
H
H
Castro-Henriques
A
A
Sarmento
A
A
Guimarães
S
S
D004279:DNA, Viral / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D016174:Hepacivirus / Q000302:isolation & purification; D006509:Hepatitis B / Q000150:complications* / Q000473:pathology / Q000628:therapy; D006515:Hepatitis B virus / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications* / Q000473:pathology / Q000628:therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000601:surgery*; D016030:Kidney Transplantation; D008099:Liver / Q000473:pathology / Q000821:virology; D018579:Patient Selection; D011994:Recombinant Proteins; D012008:Recurrence; D006435:Renal Dialysis; D014766:Viremia / Q000453:epidemiology
D004279:DNA, Viral; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins